Trial site
Uniwersytecki Szpital Kliniczny Nr 1 Im. Prof. Tadeusza Sokolowskiego Pum W Szczecinie
Szczecin, 71-252, PolandEU-13 widening countryNot linked to an institution yet
- 20running trials
- 3closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 29 trials
- Phase 2/33 trials
- Status
- Recruiting14 trials
- Active, not recruiting5 trials
- Completed3 trials
- Not yet recruiting1 trial
- Suspended1 trial
- Lead sponsor
- Amgen Inc.2 trials
- Immunovant Sciences GmbH2 trials
- Medical University Of Lodz2 trials
- argenx1 trial
- Children's Oncology Group1 trial
- and 16 more
Running trials
Recruiting
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
2026-526654-14-01· Phase 3· Janssen Cilag International· Source
Not yet recruiting
A Randomized, Double-Blind, Phase 2 Trial Evaluating the Efficacy, Safety and Tolerability of Primary Cardioprotection with Dapagliflozin in Patients with Newly Diagnosed Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation
2026-525418-67-00· Phase 2· Instytut Hematologii I Transfuzjologii· Source
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease
2025-524001-33-00· Phase 2· Immunovant Sciences GmbH· Source
Recruiting
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841· Phase 2/3· Crinetics Pharmaceuticals Inc.· Source
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004· Phase 3· argenx· Source
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT07018323· Phase 2· Immunovant Sciences GmbH· Source
Recruiting
Evaluation of the efficacy and safety of dual biologic and/or small molecule therapy in patients with induction-resistant ulcerative colitis (RESPECT).
2023-506628-98-00· Phase 2· Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy· Source
Recruiting
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
NCT06788756· Phase 2/3· Moleculin Biotech, Inc.· Source
Recruiting
Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody
NCT06688331· Phase 2· PolTREG S.A.· Source
Recruiting
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
2022-502352-31-00· Phase 3· Amgen Inc.· Source
Recruiting
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
NCT06699212· Phase 3· Rakuten Medical, Inc.· Source
Recruiting
Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care chemotherapy in children with acute lymphoblastic leukemia and confirmed activation of JAK/STAT pathway.
2024-518316-39-00· Phase 2/3· Medical University Of Lodz· Source
Recruiting
MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leukemia
2023-503394-37-00· Phase 3· Medical University Of Lodz· Source
Recruiting
Platform Clinical Study for Conquering Scleroderma
NCT06195072· Phase 2· Scleroderma Research Foundation, Inc.· Source
Active, not recruiting
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Cladribine therapy in Myasthenia
2024-517083-32-00· Phase 2· Uniwersytet Medyczny W Lublinie· Source
Active, not recruiting
AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia -
A randomized phase III study conducted in agreement with the AIEOP-BFM study group
2024-517253-27-00· Phase 3· Medical University Of Silesia Katowice Poland· Source
Active, not recruiting
Paediatric Hepatic International Tumour Trial
NCT03017326· Phase 3· University of Birmingham· Source
Active, not recruiting
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147· Phase 3· Children's Oncology Group· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error